Webinar: Expedited Programs for Drug Development

Leveraging Expedited Programs for the Development of Drugs and Biologics for Serious Conditions and Rare Diseases

October 8, 2014 @ 1PM EDT
Reserve your spot now

in partnership with Cardinal Health

FDA is committed to advancing the development of therapies for the treatment of serious conditions and rare (orphan) diseases.  As part of this commitment, FDA provides expedited pathways to decrease the development and review time for new drugs and biologics that address unmet medical needs.  In addition to these expedited pathways, which are fast track, priority review, and accelerated approval, FDA recently introduced the new breakthrough therapy designation.

This new designation will allow for more intensive guidance from FDA throughout the development process. This presentation will examine each of FDA’s four expedited programs and their impact on recently approved products indicated for serious conditions and rare diseases.

Includes a live Q&A session, and post-webinar OnDemand access for all who register.

Key Takeaways:

• FDA regulations, legal acts, and guidances governing expedited programs for serious conditions and rare diseases 
• The concepts of serious condition, available therapy, unmet medical need, and rare disease
• Understand and distinguish the differences between FDA’s four expedited development programs - fast track, breakthrough therapy, priority review designations, and accelerated approval pathway
• The qualifying criteria and features of each expedited program, as well as what is required for requesting a specified designation
• The impact of expedited programs on recent New Drug Application (NDA) and Biologic License Application (BLA) approvals
• How to leverage expedited programs to support the development of pharmaceuticals indicated for serious conditions and rare diseases

Who Should Attend:

• Professionals who wish to broaden their understanding of drug development in the pharmaceutical or biotechnology industry, including:
• Regulatory Affairs Directors/Managers
• Research and Development Directors/Managers
• Clinical Research Associates
• Medical Writers
• Quality and Manufacturing Director/Managers
• Quality Assurance Directors/Managers
• Project Managers

Reserve your spot now

PharmaVOICE is partnering with Cardinal Health Regulatory Sciences

Artificial Intelligence Tool Streamlines Drug Development

AI is Improving Drug Development

This white paper discusses how innovation will help us deliver on the promise of better medicines to patients sooner and more affordably. But technology and innovation must become flexible in order to do so, and to be flexible they must be extremely intelligent. Artificial intelligence for drug development is the future.

Download White Paper

Computing Tools that Power Breakthroughs in Drug Discovery

I found this compelling 6-minute video on Computer Aided Drug Discovery. This technology will have a major effect on the drug discovery process.

Computers can crunch drug simulations and drive innovation faster than we've ever seen in our history.

The National Biomedical Computation Resource is developing tools that will drive drug discovery to new heights. This can result in faster generation of new molecular entities, and identify more candidates for drug development, which means fatter product pipelines, and possibly better outcomes.